Arca
Skip to content
Tools
Tools

Relapsed or refractory multiple myeloma

Drug research and approvals for relapsed or refractory multiple myeloma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 99 studies of relapsed or refractory multiple myeloma are recruiting on ClinicalTrials.gov, Health Canada has authorized 66 drug trials for it since 2013, FDA has 17 approved and 0 open orphan designations naming it, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 99
  • Trials authorized in Canada: 66
  • FDA orphan approvals: 17
  • EU medicines: 3

Recruiting now

Newest posted first, of 99 recruiting on ClinicalTrials.gov ↗

How its trials ended

3,427 ClinicalTrials.gov studies of multiple myeloma in general, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 969 whose ending is known, 35% met their primary endpoint, 4% missed it and 61% stopped early.

  • Completed, result not reported1,18635%
  • Ongoing95928%
  • Met its primary endpoint33910%
  • Status unknown3139%
  • Stopped: other or unclear2718%
  • Stopped: enrollment or feasibility1645%
  • Stopped: sponsor or business decision852%
  • Stopped: lack of efficacy431%
  • Missed its primary endpoint361%
  • Stopped: safety16<1%
  • Stopped: funding15<1%

Trials authorized in Canada

The 10 newest of 66; search them all in Canada trials
Jul 17, 2026An open label phase 1b, multicenter study to evaluate the safety and efficacy of belantamab mafodotin plus cevostamab in participants with relapsed/refractory…Belantamab mafodotin / CevostamabCanadian Myeloma Research GroupPending
Jun 1, 2026Safety and feasibility of teclistamab discontinuation in relapsed and refractory multiple myelomaTecvayliCiusss De L’est-De-L’île-De-Montréal – Hôpital Maisonneuve-RosemontPending
Apr 2, 2026A phase 3 randomized study comparing JNJ-79635322 versus teclistamab in participants with relapsed or refractory multiple myeloma after 1 to 3 prior lines of…JNJ-79635322 / TecvayliJohnson & JohnsonOngoing
Mar 5, 2026A phase 3 randomized study comparing JNJ-79635322 and an anti-bcmaxcd3 bispecific antibody in participants with relapsed or refractory multiple myeloma who…JNJ-79635322 / TeclistamabJohnson & JohnsonOngoing
Jan 13, 2026An open-label, randomized phase 3 study of linvoseltamab monotherapy and relapsed/refractory multiple myeloma standard of care combination regimens in patients…Lynozyfic (REGN5458) / Carfilzomib / Bortezomib / DexamethasoneRegeneronPending
Dec 24, 2025A phase III open-label, randomised, multicentre study comparing AZD0120, a dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) therapy directed…AZD0120 (GC012F)AstraZeneca PharmaceuticalsOngoing
Jul 25, 2025A phase 1b/2a, multicenter, open-label study to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of mezigdomide in…Mezigdomide (BMS-986348, CC-92480) / Elranatamab / DexamethasoneBristol-Myers SquibbOngoing
Mar 13, 2025A phase 1/2 study of etentamig in combination with a celmod agent for the treatment of patients with relapsed/refractory multiple myelomaEtentamig (ABBV-383) / IberdomideAbbVieOngoing
Oct 10, 2024A phase 3, randomized, open-label study to compare the efficacy and safety of anitocabtagene autoleucel versus standard of care therapy in participants with…Anitocabtagene autoleucelKitepharma IncOngoing
Sep 11, 2024A first-in-human, open-label, phase 1 study to evaluate the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of subcutaneous SAR446523, an…SAR446523Sanofi-Aventis Canada IncOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 17
Mar 5, 2026TecvayliTreatment of adult patients with relapsed or refractory multiple myeloma in combination with daratumumab hyaluronidase-fihj in patients who…Janssen Research & Development, LLCApproved
Oct 23, 2025BlenrepIn combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have…GlaxoSmithKline Intellectual Property Development Ltd.Approved
Jul 2, 2025LynozyficTreatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including…Regeneron Pharmaceuticals, Inc.Approved
Apr 5, 2024CarvyktiTreatment of adult patients with relapsed or refractory multiple myeloma, who have received at least 1 prior line of therapy, including a…Janssen Research & Development, LLCApproved
Apr 4, 2024AbecmaTreatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an…Celgene Corporation, a Bristol-Myers Squibb CompanyApproved
Aug 14, 2023ElrexfioTreatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including…Pfizer Inc.Approved
Aug 9, 2023TalveyTreatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including…Janssen Biotech, inc.Approved
Oct 25, 2022TecvayliTreatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including…Janssen Research & Development, LLCApproved
Jun 30, 2022KyprolisTreatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination…Onyx Therapeutics, Inc.Approved
Feb 28, 2022CarvyktiTreatment of adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome…Janssen Research & Development, LLCApproved
Nov 30, 2021KyprolisTreatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination…Onyx Therapeutics, Inc.Approved
Mar 31, 2021SarclisaIn combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who…Sanofi-Aventis U.S. LLCApproved
Mar 26, 2021AbecmaTreatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an…Celgene Corporation, a Bristol-Myers Squibb CompanyApproved
Feb 26, 2021PepaxtoTreatment, in combination with dexamethasone, of adult patients with relapsed or refractory multiple myeloma who have received at least…Oncopeptides ABApproved
Aug 20, 2020KyprolisTreatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination…Onyx Therapeutics, Inc.Approved

Medicines authorised in the EU

Newest first
Jul 23, 2025BlenrepBelantamab mafodotinGlaxoSmithKline Trading Services LimitedEMA ↗
Apr 23, 2025LynozyficLinvoseltamabRegeneron Ireland Designated Activity Company (DAC)EMA ↗
Aug 23, 2022TecvayliTeclistamabEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.